they mean well but it's like pharma as saying here is a huge gedmgrac ofpal sts. >>t:hi'mll lile bit and go on to the second half of the book which is calledbig food in here. so you start off a big food, again, talking a anise wereng ta sen laese ceitanlmsacs. again, i am wondering why you started there. and what do yousee as the danger with milk which is someing tmostaerican k rtss glofkt eav ifft t milk now than may be ten 15 years ago even? >> guestas younow ihave a chtelle r rinka loan srish hle whabeifnt f course the growth hormone which was made by roxanne the was a kinf reduedbut s a e eteatn15 s us two rred o efihg ong with milk would be fat and so many consumers so we don't on these artificial hormones in the wewao t. eug thcogwhdd call factory farming, which is a very intensive way of raising esalilwt drugs so they are called destroying the meat. in other words it's not just the mihe cows that are raised mcld o o fop dn rn milk, the drug tests raised in the factory rming situation. >> host: when you decided to taboliild otf the es avhae en th ssues.ofent

go to twitter @jimcramer, #stockderby, to choose among arena pharma, onyx pharma, u.s., melanex technologies or pharmacyclics. let's speak to bill in florida. bill >> caller: jim, thanks for taking my call. >> no problem. . >> caller: what do you think about green mountain coffee? down from over 100 in the past year. it traded around four times usual volume on friday, and it was up over $1 in a down market. >> people are always going to try to call a bottom in something that doesn't have good fundamentals. i've been skeptical of it ever since @herbgreenburg on twitter introduced the concept of perhaps the numbers being way too high. i'm going with ed greenberg. all right, play ball. in honor of in celebration of all-star weekend, the home run derby, i'm letting you vote. tweet me @jimcramer, #stockderby, and vote for which stock you think is going to be the biggest home run hitter in the second half of the year. and stay with. . >> coming up, healthy breakup? five years after its spin off from tyco, covidien has become one of the largest providers of health products. wi

and in some cases they were kind of anti-pharma. spmaut just you know, of the the raw data is one clue. if youan look at what they have written throughout the to e r heiouslu want om f y ko. t knofrs a jona y ae seeking the truth, you know, but most of my interviews in here were really not ith phapctor psats -- and i had some of the psychiatrist tell me that their whole group were caribbean isndscre onpi thatind thi, ital annesodouin y know, i do think the money is kind of the bread of the problem. i do. >> host: that beingidi gus we se oft yorhk ha tl u bevesfou veisniboho want to talk to in order to do your reporting. who were some experts i guess if you are able to gain the trust of and who areil to lk ou ero ckndoronan wrg hi kck ue well, a lot of my researchame from the original documentation, from the medical journal and i wld have to sy i e erisloso tterery isffg ndt o thing. i have one story in there about a doctor in texas whoha an so, in the case he gave me many of many documents and i interviewed him but also interview th

first up, arena pharma.t has rallied an astounding, a whopping 225% on the strength of its newly approved anti-obesity drug belviq. what's the big deal? how about the fact that this is the first drug for obesity in more than a decade. it works better than the last one that was approved without the apparent high heart attack ratio of its predecessor. a drug which defined half of the eternal truth that you can never be too rich or too thin. i'm not going to tell you it's a slam dunk. the drug probably won't be on the market until the second half of the year. second place, onxx pharma up 76%. this is a sleeper. with a surprise new drug which treats multiple myeloma, blood cancer in the bailiwick of celgene. the fda gave the drug the thumbs up which shocked people. coupled with the already proven celgene entry. that's one reason why the stock shot up like it did. the other is possible take over chatter since a wonder drug for the previously untreatable kidney and liver cancers has performed so wellment when you

>>> keep your eye on onyx pharma. we'll see what happens when it's released for trading in a little bit. in the meantime, dow is down 87. that does it for us at "squawk on the street." time for "the halftime fast money report" back at hq. >> welcome, everybody. i'm brian sullivan. we're 2 1/2 hours into the trading day. here is where we stand. there's a lot of red on that screen. as you can see, most of the s&p is down and we are 86 points off the dow. what about the commodities, both hard and soft? let's take a look at crude oil. crude oil is down and gold is up very fractionally. here's what we are following on the day. why they are negative on the market. healthy returns. pharma stocks hitting new records this week and we have a top analyst. pain in spain. hey, newsflash, america, europe still a mess. it is not fixed. we are making drown what you should be watching for next and how to trade it, if traded at all. welcome to the "half-time report." what are you watching in the market today? >> the amg. he couldn't bu

one of the fastest growing big pharma names up there.t's not easy to understand, so it's fantastic that the management is splitting the company into a branded drug business and diversified medical products. it sells everything from nutritionals to diagnostic products. the pharma division can stand on its own facing fewer big patent expirations than the competition and the medical products deserve to be in a different company. the drugs take forever to be approved. this is about creating two stocks that deal to a different constituent of money managers. you can get a nice dividend vehicle, a growth vehicle. and both companies deserve to go higher, especially in a recession where portfolio managers pay for consistency. fourth, man, we have to have domestic security in the worldwide slow down. what could be better than a domestic security play with a bountiful dividend and a business as consistent as it gets? i'm talking about consolidated edison. mr. ed or con-ed, the new york based utility with a hefty yield. it is a transmission and dist

there's many, many medical professionals now who are paid by pharma. as you say they write the articles. and so, the whole thng i lv. ybtsp owok at sga that their mindset is that we are not judged by a how many people reject. so by definitionieon t. ththofste are and i think in many cases we see is actually better. the biggt problem with all the dangerous drugs they read about in the bok is fthi ot o ir-n a thhe oha we all really see it except for big pharma. >> just going back to the discussion of having experts write in myjournal. reon ho oinhat kind of esthm thu mps order for you to think thatheir writings might be biased or maybe opions should be taken with a little bit of skepticism because there are, you know, you mentioned experts who hve beenpaide g tnd bu is that the same as having a financial ties? where should we be looking for this? >> i may be naÏve, but i believe as aro c veasmu a f coffee -- same applies to medical professionals. well, i got an honorary but it doesn't affect my udgment. evfte otottu. bee mo taken -- even five years ago i

>> guest: big pharma went to the direct consumer advertising anddeeg a lewatopbeeit t i twapn to b parma. what's wrong with a command line against the took pede ltelly,e ibiskaa thru ha this condition and i need this drug and he or she is going to say probably yes. so anywayitos rur mel rfsalni al eehat esa ofchoia he people who are flying are suddenly not find. >> host: one of the roles in that the pressure nw bn acnuficiak f dioou nwee of the responsibility then the patient themselves like how much of this do you feel like s maybe exceeding the infoation and how c tchoce atkofoen ma umtaryb ff frmt hr i eating us? >> guest: having been in advertising, i really learned e ft. wa genthae ird adi i pna o a bcalkdhed dever looked at the car t if i looked i bought that exact car. ads work sublinally. t leca o f thtv hytre s sethtoes e he suinly. the responsibility is to realize that a lot of hsexdrugs pe werta frnean esncndot of your doctors are affected by the advertising and may not realize at. ht:mon b u edut ahe ta leity tht dos s eald fda cannot with guides i believe it was in 1997 abou

, the pharma lobbyist writing, "confidential. the white house is working on some very explicit language on importeddation to kill it" -- to kill it -- "in health care reform." in august 2009, pharma's top lobbyist at the time, billy tozat, made it crystal clear as well -- quote -- "we were assured you will have a rock-solid deal." well, mr. president, the tragedy of it all is they apparently did have a rock-solid deal. because if you look at u.s. senate votes after that back-room deal which helped pass obama-care, there were multiple individual u.s. senators who flipped their votes, made good on the white house rock-solid deal to kill reimportation, that opportunity for all americans, particularly seniors, to be able to buy safe, cheaper prescription drugs from canada and elsewhere. let's look at votes on the broad reimportation bill led by then-senator byron dorgan. i was a cosponsor. so were many other senators who have been involved in this issue. john mccain, olympia snowe, many others. in 2007, the senate actually passed tha

but one of them -- one that i continue to wonder about is the business model of big pharma.y like glaxo -- does it have anything in the pipeline that will replace a paxil and is that why they're desperate to maximize the profits from these pills? >> well this has been an issue across the pharmaceutical company industry. we have all of these huge blockbuster drugs that are now kind of reaching what they call the patent cliff when they lose their exclusivity. yeah there has been in many of these cases you know, difficulty kind of replacing some of these huge drugs and right, so they -- these companies do want to try to squeeze as much as they can. >> the pressure for offlabel marketing is enormous. the other thing dr. wolfe we'll have to continue this conversation is to have complete transparency about clinical testing data so it makes it harder to offlabel because then everybody would know what the risks would be. director of public citizen health research group dr. sidney wolfe, "new york times" reporter katie, thank you for your time. >> nice talking with you again. >> glax

in other words, it isn't even in the same sector as your pharma position.here really isn't any overlap. that's how different they are. this is speculation. the essence of good speculation is to take some profits as you get them, no matter how good or how hot the stock might be. how hot the stock might be.. your ultimate goal should be to ring the register on your initial investment so you can play with the house's money, which is why i was so adamant last night that people with big gains in arena, and you know you're out there, simply must ring the register on at least some if not all of their profits. playing with the house's money is the holy grail of investing because no matter what happens you can't lose money. you're playing with pure profit. listen. you have to be willing to be skeptical of any stock you own, even your favorites, something i talk about all the time with my colleague herb greenberg, simply because it makes you a much wiser investor. you have to be willing to see the other side of the trade. you have to know the bear case against you, n

and the winner, arena pharma. overwhe overwhelming, 67.1% of the vote.eople have spoken and their choice is crystal clear. you think arena has the best shot by far in the second half the of the year. we know the voters liked arena pharma by a big margin, but are they right? analyzing it through the lens we use to evaluate any tech stock. in the second quarter, it rallied 2.25%. it's already had a truly phenomenal run. it doesn't have any products on the market, let alone any profits. the secret to arena's success is a weight loss drug. the first obesity drug they've approved in more than a decade. of course, we have an obesity epidemic here in the united states, so this could be a huge market. the analysts who cover the stock say peak sales with a con sus around $6 billion. it could be cheap even after its massive run, considering it has a market cap of $2 billion .. all of this sounds sdarn sexy. but i worry it won't be able to live up to the hype. and honestly, the fact that so many people voted for arena makes me a whether itle more skeptical. we like

i think onyx pharma has a better shot of outperforming here.ng to be my vote, because it is likely that the f diamondbacks a will approve the blood cancer drug and that would give them two products on the line. the bottom line, the results of the all-star home run derby is in, and arena pharmaceuticals is the people's choice, but i don't believe that it can live up to the hype. the fact that so many people like it makes me think that the upside is too much. and if you have been riding this one, i reiterate what i said last night, sell it and let the rest ride, and if you are worried about the sideline, then take the stock and play with the house's money. linda in connecticut. >> caller: hi, cramer. how are you? >> not bad. how are you? >> caller: i went to the market and got some new jersey peaches, and they are good. >> i am not kidding that my tomatoes are a couple of weeks late, but they are good already. >> caller: it is fabulous. here is my problem. i have a stock that is running with the bulls and they collaborate with world leading pharm

reportedly gave dream pharma the green light to sell a drug called sodium pentothal to several states this drug is raising questions of constitutionality and whether the use of that can be considered cruel and unusual punishment to discuss this rayman bodner author of the book and natalie of justice a murder case god ron. raymond welcome so i mean what do you think can using this drug be considered cruel and unusual punishment. the supreme court has said that lethal injections in not cruel and unusual doesn't violate the eighth amendment the prohibition on cruel and unusual punishment but at the same time it effectively said that the drug has to work and if the right if the administration of the anesthetic which is one of the three drugs used in the lethal injection protocol is ineffective or isn't say that it might be subject to the person being killed the prisoner to cruel and unusual punishment and what is it about this drug sodium pentothal i mean how does it work and why is it more controversial than other drugs use and lethal injections but it's it's it's an anesthetic liz and i

take a look at the rails, the big pharma names. everything is participating in this rally. the vix is now below 17. >> mike murphy, do you agree? >> i do agree. the last few weeks, we've had negative news out in the market and yet the market has held its key levels. now with the s&p above 1,350, you have to look exactly like pete just said, get some protection. you have earnings really heating up next week. although jpmorgan and wells fargo had great numbers today compared to what was expected, things aren't so great out there. i think earnings could disappoint. if you have some money on the table here, you want to take some off on this rally. >> joe terranova? >> you have to ask yourself, all week, there's been a tremendous amount of negative news, a lot of the bears telling you to run for cover in this marketplace. the market's not gone down this week. and then today you get the financials which has been the catalyst all year to date. it is the catalyst again today. you look at jpmorgan or jp dimon -- >> you can call it that. >> jpmorgan has now cleared the path for the r

what i like in pharma is growth, pure growth, based on potential blockbuster drugs that you can provide growth. that's what gilead, am jen and sell ya was giving you. finished at 52-week high for am jen products that can work in cases were others failed. doesn't hurt the core business is on fire. many people believe the best compound for hep c. people wrote this company off, but confident the franchise remains intact and thriving and number of initiatives sell gene has could lead to earnings outside. it is an inexpensive stock with many years of growth. i said that even after the stock went over $3. you know i like dividends, don't like expensive stocks. if anything, one particular drug prospect goes awry, but the three old biotech companies proved themselves time and time again, while they aren't for the feint of heart, you can get long-term growth that you can't get from a merck or pfizer or abbott labs. these companies are the risk taker, not afraid to make mistakes, innovate relentlessly, spend fortunes developing new drugs and remind me how the old-line pharmas used to be in the pr

what i like in pharma is growth, pure growth, based on potential blockbuster drugs that you can providewth. that's what gilead, amgen and sellya was giving you. finished at 52-week high for am jen products that can work in cases were others failed. doesn't hurt the core business is on fire. including the older drugs which were responsible for delicious upside earning surprise. many people believe the best compound for he c. it could be worth billions and billions. that could be as early as 2014. it has made many people believe that the best compound is gilead's. they were much better than expected. people wrote this company off, but confident the franchise remains intact and thriving and number of initiatives celgene has could lead to earnings outside. given its stellar profits, much better than expected, it is an inexpensive stock with many years of growth ahead of it. i said that even after the stock went over $3. you know i like dividends, don't like expensive stocks. if anything, one particular drug prospect goes awry, but the three old biotech companies proved themselves time and t

prescriiing it even though it's only approved for adults.the f-d-aaasked ooycontin's maker-- purdue pharma conduct a studd, offering the companyyan incentiie to extend its patent for six months on &poxycontin..... which would translate into huge profitt. 21-29"my concern is the reason phey're nterested in this research is that hey ant to get pproval to market the drrg for use in children." children."116-128"it's not fair to he hild tt withhold &pa treatmmnt that can help he recover and feel better and be " proddctive." the sttdy's criteria for ts 154- patients include... the phild must be between six and puffering from moderate to severe pain.. and must already be receiving treetment with ooioids. pf you use a baby monitor... be careffl wheree ou place it. safety advocates are warning parents about the danger of ccrdd used for the monitors. the cords have been responsible for at least sevee deaths of infants and toddlers. p01-112"that's not just true for electric line cordsson monitors. that's true for drapery corrs and window blinds and any other corded equipmenn around the nursery.. keep

>> caller: our stock is atrs, antares pharma.evenue increased and they have several large license agreements with large pharmaceutical companies including teva watson and pfizer. what do you think of the long-term prospect? >> all right. we have had mixed success with these injectables. we have to do more work on this company. we can't just opine on it. this business has been up and down. i promise to come back. i don't have a ready answer. tom in illinois. tom. >> hi, jim. how are you doing? big boo-yah from illinois. >> what's going on? >> caller: we call this the land of the overtaxed. a question for you. i have been in and out of f5 networks. there is short selling going gone at this point. what's your opinion? >> i was surprised there is so much negativity. i'm going to tell you i would rather see you in salesforce.com. that's a better cloud play. i'm willing to stick my neck out with the only deep in the money call. that, ladies and gentlemen, is the conclusion of the lightning round. [ buzzer ] >> announcer: the lightning

that was hell was going to happen, the weapons were going to be turned over to the shift pharma? >> that was my impression, yes. >> when you left the meeting, it was your impression the weapons would be turned over to the sheriff's department and not the police department? >> yes, as instructed by my attorney. >> based on the conversation with your attorney or based on the conversation with the inspectors? >> well, my attorney was present during the conversation. based on the conversation taking place, i a understood the weapons would be turned over to the police department but over the saturday it would be handed over to the sheriff's department. >> this was a discussion you had with the inspectors? >> no, it is what my attorney had instructed or suggested to me. >> your information about any conversation that may have been had with the inspectors is not first hand? is that correct? >> yes and no. part of it was first and and part of it was not. >> on the specific issue of whether the weapons would be turned over to the sheriff's department rather than the police department, wer

merger monday, major deal for big pharma. who could be next to get an m and a bump. welcome to halftime report. lots to trade. the chart of the day. find out what the traders are talking about. ism report taking air out of stocks today, a reading under 50, signaling contraction. new orders showing particular weakness. stephanie, how worried should we be. yes, we know the economy is slowing, now we're going to hear people talk about recession? >> you will. looking at 1.5 gdp expectations is the best case scenario, particularly with new order component, the rumor was it would fall to 50. 47 1/2 is disappointing. your can make a case it's not as bad if you look at the construction spending numbers. the construction spending numbers were better than pequoted led by residential, which i think is also encouraging. so housing is still kind of bottoming. i think that's okay. the consumer is okay on the industrial side of the ledger you have to be a little more concerned. >> new orders dropped like a stone. ism services out later in the week, perhaps a little more important b

but the focus is bio pharma and medical devices. >> best of luck with you.thank you. >>> coming up, more on super mario draghi and the markets when we come back on "power lunch." oahhh! [ male announcer ] it made a big splash with the employees. [ duck yelling ] [ male announcer ] find out more at... [ duck ] aflac! [ male announcer ] ...forbusiness.com. ♪ ha ha! [ male announcer ] this is our beach. ♪ this is our pool. ♪ our fireworks. ♪ and our slip and slide. you have your idea of summer fun, and we have ours. now during the summer event get an exceptionally engineered mercedes-benz for an exceptional price. but hurry, this offer ends july 31st. is now within your grasp with the e-trade 360 investing dashboard. e-trade 360 is the world's first investing homepage that shows you where all your investments are and what they're doing with free streaming quotes, news, analysis and even your trade ticket. everything exactly the way you want it, all on one page. transform your investing with the e-trade 360 investing dashboard. >>> let's talk markets. kenny, i w

inside a bio pharma stock more than doubled this year. straight ahead. >>> plus, weathering the storm. the impact this weekend's wild weather is having on retailers. also taco town usa. the dreams of one very small place in alaska. >>> meantime, let's look at the markets. new month, well it's not quite come out like the old one went out. but today, it's been down for most of the session after an early gain. a similar story over at the s&p 500 which had the best june since 1999. but it's been modestly lower for most of today's session. nasdaq holding its head slightly above water today. the outperformer and adding to a better than 12% gain so far for the year. check in with mary thompson on the floor of the nyse and jackie at the nasdaq. you, first of all, mary. the clunk we are the disappointing manufacturing data this morning. lit a little birth of a fire under those wanting qe3 and maybe a floor under the market, as well, do you think? >> certainly that chatter started right after the manufacturing data, mandy. it was disappointed and f

we talked about big pharma. this is one of those names you sometimes forget to mention. they do an outstanding job. look at these valuations. i like this name. i'm not in this name. i've been in it in the past. i'd also highlight halliburton. beaten up. we're seeing that sector see a lot of activity when you're talking oil, gas, everything this feeds into it. >> on the capital one financial story that's a stock today down 2%. leon cooperman as i said just unveiling that as one of his top picks here at delivering alpha. as i mentioned, the interesting note here is that consumer finance protection bureau taking its first enforcement action today against capital one. ordering it to refund $140 million to some 2 million customers for what it says was deceptive marketing practices. of course, richard cordray chairing that. some interesting news on a day when leon cooperman lays it out as one of his top picks. brian kelly, any thoughts on that? or some of the other names on this long list from lee cooperman? >> capital one is the one that really struck out to me. the first thi

taken another gold in the judo with bats plus all the rest of the news from london here's a hundred pharma. so i want to start for russia no we've only had three days of competition so far but russia have been amongst the medals for the third day running and their judo team have got a second goal that came from montreal is the live in the seventy three kilogram category he beat japan's world champion ricky in a car in the final a man he hadn't beaten in six previous attempts and he did it with the yukon and that effectively means he threw his opponent on the side that happened in the final minutes of this five minute contest is a true olympic champion who came into this contest ranked number four but he blew away a host of big names including south korea's ki-chan wang in the semifinal much to the delight of russia's judo loving president vladimir putin but of course no one is more delighted than is di if himself although. i had a solid game plan for the clash my coach told me all i had to do it was crucial to neutralize my opponent's stronger hand and prevent him from doing any effective

the podium where the country intends to leave its mark with more from the english capital his andre pharma. after seven years of planning and at a cost of fourteen billion dollars london is finally ready to stage the biggest show on earth and russia has arrived here with the i'm a finishing third in the medals table the majority of the squad on ice settling into the athletes' village based at the olympic park in the north east of the city that is where the majority of medals will be won and lost over the next two and a half weeks and to give us a flavor of what it's like up there is that you've ample flipped over sparsely furnished just behind me there will be five ten thousand sportsman and official state individual hoarsely games including the four hundred also russians these two thousand told me i don't walk around. but we could go also but again as i was very very impressed with the whole sense that it was a much improved from beijing years ago that's all now face to. face with the press or. someone who speaks the truth so help us really we should enjoy this story speaking small but no

time so let's hope the russian team can keep that medals tally ticking over until the end andrew pharma. london. let's move on to russian football where it's headed cross they have claimed their first win of the season after beating f.c. krasnodar one nail on home pitch eighteen minutes were all that stunned his lot church of his men needed in order to get to that victory even all headed in his second goal of this year's game in the campaign to seal the finals for all one nil to take already in the first half so grass' they are now in the standings with four points while cross the seventh with three. now russia's first ever world class motorsport track has been tested out in the moscow region a four time formula one champion alan process among those in attendance for their rental world series event course that's important was there as well. four years ago few dram to moscow would have its very own world class more a sports wreck today even a month ago you could heal new workers here and the quickest car was nowhere near formula one levels but the dream finally came true and high octane

the department does agree with the planner 3 in pharma to review. on the bottom of page seven. finally, on page 8, the department disagrees with the planner 3 in march interview with a savings of 144,555. supervisor chu: thank you. the department agrees with that assessment? >> that's right. supervisor chu: let us take the areas where there is agreement by the department. this just leaves out the positions currently. motion to take the areas where there is agreement? yes? ok, without objection. with regard to the remaining items, colleagues, my preference, rather than stripping it out and potentially adding it back in, what we can do is come on thursday, we can leave these items out until thursday and look at all of our priorities as a whole. from my point of view, the environmental review positions that are dedicated general fund department items or general fund projects, i think, is an important one. tins to be areas where we fall short when we talk about not delivering bond projects on time, all the delays, what it means to taxpayers when people do not see their projects com

the capital are covering their windows for fear of snipers and strong you know keep in touch with pharma addicts on a boycott underscore our. america's pristine track record of drone strikes in pakistan the syria has become a source of pride one hundred fifty militants dead and no civilian losses but experts say those figures from the new america foundation just don't stand up the white house to creese any men killed by drones as guilty until proven otherwise and with more on those numbers here's our washington correspondent cam. if you believe this chart as seen on c.n.n. american drone strikes in pakistan have been so precise that they haven't killed a single innocent person this year the chart shows last year the strikes targeted four hundred thirty one militants and killed only twenty six quote unquote others meaning civilians the data was compiled by the new america foundation now how did this foundation come up with the numbers which look pretty much like advertising for drones they link press reports when you actually look at the reports reports almost half of them are attributed

people on one side and all of these big bad industry folks, insurance companies we all hate, but pharma, the doctors' groups on the other side fighting him. they were all on one side cutting deals with each other and the american people were on the other side. >> i would simply say a lot of industry stakeholders do not favor freemarket reforms for this reason. we spend more per capita on health care than any other company -- country. if there is a market system that encourages individuals to allocate money more efficiently, a lot of that will go to health care. >> there are six major pharmaceutical companies. they began the conversation that cold industry into the obamacare negotiations. in the case of every one of those six companies, the ceo departed or left under other circumstances, as well as pharma. your humble whole different team of people that are going to be a misreading the next phase. they're not as invested as the folks who made the deal in the first place. >> i will take you and in the last two. >> i would appreciate it if you could elaborate on governor romney ' as ideas

it's going to be fine for big pharma and big insurance. i think -- that's why, you know, big pharma spent $150 million lobbying for this bill. they showed up at the white house. went over and met with the president and came out with all sorts of agreements to spend money in campaigning for this bill because they know every insurance plan in america has to coffer their prescription drugs, there's going to be a whole bunch of new expansions in medicare for them, they're going to have brand name drugs covered under the doughnut hole where they were going to generics and stuff. so they came out ahead. big insurance, you know, they dropped the public option, and they got a mandate that people have to buy their product. a $70 billion a year bailout for the insurance industry. now, the small and medium companies can't comply, they're going to go out of business, but that's great for the big insurance companies who are going to control the last little bit of the market. the ama lobbied in favor of this bill because with, because they think that's

drug maker purdue pharma says the young patients have diseases such as cancer or sickle cell anemia..s such as severe burns.. or pain after surgery. the company is seeking fda approval for oxycontin use in children. doctors currently can prescribe it off-label to pediatric patients. if you want a baby, quit smoking before trying to get pregnant. that's the advice of french scientistss who found embryos of smoking mothers develop more slowly... suggesting the eggs of smokers were affected. the researchers used time lapse photography to look at embroys from the moment they were fertilized until they were ready to be implanted. at all stages of development embryos from smokers were consistently a couple of hours behind. the study could not say what impact the slower development has, or if this affected the chances of having a child.. but the lead researcher says he would advise women who want to get pregnant, to kick the habit. vitamin d can prevent fractures in older women.. but the latest study finds only larger doses produce this benefit. swiss researchers found taking more than 800 i

. >> another gift for big pharma. you can't use it for the generics or the drugs over the counter, instead you get a prescription for a brand name drug. >> i would just like to end it by saying i guess like we say at the heritage foundation, details matter. and the more the american people know the details, i think the less that they will like it. so thank everyone for the panel. we do have books available when you came out so, please, feel free to pick one up. but let's thank the panel one more time. [applause] >> every weekend booktv offers 48 hours of programming focused on nonfiction authors and books. watch it here on c-span2. >> and now booktv sits down with jonathan karp, executive vice president and publisher of simon and suiter, and morgan entremendous ken, publisher of grove atlantic to discuss the publishing world from bookexpo america, the annual trade show for the publishing industry. this is about half an hour. >> you're watching booktv on c-span2, and we are on location in new york city at the annual bo

order to cope with their emotions but who's really prescribing the cure to happiness doctors or big pharma will tell you the truth about antidepressants. and technology is taking a sexy turn these days as the porn industry pioneering the way for the use of google glasses we'll show you why your adult video experience could get a lot more up close and personal in the near future. it's friday july thirteenth seven pm here in washington d.c. i'm liz wall and you're watching r t o made in america that's a label that is rare these days and now there's controversy over the u.s. as a limp dick teams uniforms not being made and the usa but maybe they should take a look at the athletes and where they're from turns out a number of olympians were not made in the usa either here's a few of us lopez a long you know he's in track and field he's actually from south sudan and there's meb. also long distance running he is from rich rhea. and lastly there is a deal hakeem mon he is also a long distance runner he is from the country of somalia and that's just what we found in track and field but while the me

free gifts like tote bags so ok mr mair way to take on the evil formula companies forget about big pharma that's pushing highly addictive psychotropic meds on kids in fact forget all the other important issues facing your city to write seems like it kind of refer that from stopping for is to warrantless surveillance to inequality. it seems like the mayor has been wrong on every major issue and perhaps by is why he's continuing his war and personal freedom promoting an ineffective self-righteous crusade to distract the voters from the real issues but whatever the real reason is bloomberg just cannot seem to stop ruling with a heavy hand so for that he wins again tonight's told time lord. our guys it's time for a last raise and i felt when we come back we'll have an extra special happy hour for you my grades are going to joy be a lower show team and i will be getting you off very well after two and a half years but put away the tissues there are plenty of ridiculous stories to talk about so sit tight. if they shoot something inappropriate for public they can easily be. my. guest he's a war